GSK plc (BVMF:G1SK34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 520.62B +22.5% |
| Revenue (ttm) | 242.17B +4.1% |
| Net Income | 42.37B +122.0% |
| EPS | 10.29 +123.2% |
| Shares Out | n/a |
| PE Ratio | 12.29 |
| Forward PE | 10.24 |
| Dividend | 1.80 (3.32%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 5 |
| Average Volume | 10 |
| Open | 52.25 |
| Previous Close | 54.30 |
| Day's Range | 51.65 - 52.25 |
| 52-Week Range | 39.98 - 63.24 |
| Beta | 0.35 |
| RSI | 26.41 |
| Earnings Date | Apr 29, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK PLC (GSK) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Pipeline Expansion
GSK PLC (GSK) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Pipeline Expansion
Q1 2026 GSK plc Earnings Call Transcript
Q1 2026 GSK plc Earnings Call Transcript
GSK Faces Setback as Nivisnebart Trial for Alzheimer's Discontinued
GSK Faces Setback as Nivisnebart Trial for Alzheimer's Discontinued
A Look at GSK PLC (GSK) After 5.6% Decline -- GF Value $43.80 vs Price $51.40
A Look at GSK PLC (GSK) After 5.6% Decline -- GF Value $43.80 vs Price $51.40
Big pharma can boost Britain: Labour must not let our flagship firms drift away, says RUTH SUNDERLAND
One area where the UK still performs well on an international stage is pharmaceuticals, led by AstraZeneca and GSK.
AstraZeneca (AZN) and GSK Report Strong Q1 Earnings Amid Pricing Policy Concerns
AstraZeneca (AZN) and GSK Report Strong Q1 Earnings Amid Pricing Policy Concerns
GSK Reports Strong Q1 2026 Results with Revenue Growth
GSK Reports Strong Q1 2026 Results with Revenue Growth
GSK Declares Quarterly Dividend of $0.44, Initiates £2 Billion Buyback
GSK Declares Quarterly Dividend of $0.44, Initiates £2 Billion Buyback
GSK Raises 2031 Sales Forecast to Over GBP 40 Billion
GSK Raises 2031 Sales Forecast to Over GBP 40 Billion
GSK Reports Strong Q1 Sales Growth and Advancements in R&D
GSK Reports Strong Q1 Sales Growth and Advancements in R&D
AstraZeneca (AZN) and GlaxoSmithKline (GSK) Exceed Q1 Earnings Expectations
AstraZeneca (AZN) and GlaxoSmithKline (GSK) Exceed Q1 Earnings Expectations
Shot in the arm for GSK and AstraZeneca from cancer drug sales
The blue chip drug makers saw first quarter earnings beat market expectations.
GSK plc Earnings Call Transcript: Q1 2026
Q1 2026 saw 5% sales growth to £7.6B, led by Specialty Medicines and Shingrix. Operating profit rose 10%, EPS 9%, and cash generation was strong. Guidance for profitable growth is confirmed, with pipeline acceleration and disciplined capital allocation ongoing.
Vaccine Star Shingrix Lifts GSK, But Weak Segments Raise Eyebrows
British pharmaceutical company GSK Plc (NYSE: GSK) on Wednesday reported first-quarter core earnings of $1.25 per share (46.5 pence), beating the consensus estimate of $1.17. Earnings rose 4%, or 9% ...
Cancer drug demand helps AstraZeneca and GSK boost their bottom lines
Pharmaceutical drug giants AstraZeneca and GSK both saw cancer drug sales rise in their latest quarter.
UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giant...
GSK Reports Strong Q1 Earnings with EPS of £0.465, Revenue of £7.63B
GSK Reports Strong Q1 Earnings with EPS of £0.465, Revenue of £7.63B
GSK Earnings Boosted by Higher Specialty Medicine Sales
The pharmaceutical giant said core operating profit for the first quarter was £2.65 billion compared with £2.53 billion for the same period a year earlier.
GSK Q1 Core Profit Rises; Affirms 2026 Guidance
(RTTNews) - GSK (GSK, GSK.L, GS71.DE) reported first quarter pretax profit of 2.14 billion pounds compared to 2.11 billion pounds, prior year. Earnings per share was 42.6 pence compared to 39.3 pence....
GSK beats quarterly profit estimates on strength in respiratory, general medicines
British drugmaker GSK reported first-quarter profit above analysts' expectations on Wednesday, helped by strong sales of its respiratory and other general medicines.
GSK to Report Q1 Earnings with Strong Revenue Expectations
GSK to Report Q1 Earnings with Strong Revenue Expectations
GSK Receives FDA Priority Review for Bepirovirsen in Chronic Hepatitis B Treatment
GSK Receives FDA Priority Review for Bepirovirsen in Chronic Hepatitis B Treatment
FDA Accepts Priority Review And Grants BT Designation For Bepirovirsen In Chronic Hepatitis B
(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) partner GSK on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for Bep...